-
Apr 06, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
-
Mar 10, 2022
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
-
Mar 02, 2022
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
-
Feb 07, 2022
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
-
Dec 30, 2021
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
-
Jun 09, 2021
Founder and CEO of Antengene, Dr. Jay Mei, talks innovation in biotech, passion and learning from our mistakes
